F2G gets olorofim breakthrough therapy status from FDA for mold infections
F2G has secured breakthrough therapy designation to olorofim (formerly F901318) from the US Food and Drug Administration (FDA) for the treatment of certain invasive mold infections. The breakthrough therapy designation is for the use of olorofim in patients having limited or no treatment options, and also those who are intolerant to currently available therapy for […]